Medicine and Dentistry
Patient
100%
Therapeutic Procedure
57%
Mycosis fungoides
57%
Diseases
30%
Nodular Melanoma
28%
Neoplasm
24%
Cutaneous T Cell Lymphoma
23%
Combination Therapy
23%
Diagnosis
22%
Cells
17%
Psoriasis
14%
Inpatient
14%
Cutaneous Lymphoma
12%
Skin
12%
Apoplexy
12%
B Cell
11%
Analysis
11%
Tissues
11%
Plaque
10%
Phototherapy
10%
Syndrome
9%
Melanoma Cell
9%
MEK Inhibitor
9%
Epithelioma
8%
Radiation
8%
Metastatic Melanoma
8%
Dermatology
7%
Chondroitin Sulfate
7%
Monoclonal Antibody
7%
Chlormethine
7%
Leg Ulcer
7%
Actinic Keratosis
7%
Sorafenib
7%
Hepatocellular Carcinoma
7%
Carney Complex
7%
Lymphoma
7%
Sneddon Syndrome
7%
Vasculotropin
7%
Melanocytosis
7%
Pyoderma gangrenosum
7%
Clusterin
7%
Antibiotics
7%
Survival
7%
T Cell
7%
Phenotype
7%
PUVA
7%
Chemotherapeutic Agent
7%
Drug
7%
Lesion
7%
Prevalence
7%
Messenger RNA
7%
Mast Cell
7%
Comprehension
7%
Adverse Event
7%
Talimogene Laherparepvec
6%
Quality of Life
6%
Hypoxia Inducible Factor 1
6%
Carotid Artery Stenosis
6%
RNA Sequence
5%
Blood
5%
Age
5%
Recurrent Disease
5%
Association
5%
Development
5%
Vemurafenib
5%
Nonsense Mutation
5%
Exome Sequencing
5%
Pediatric Stroke
5%
Meningitis
5%
Magnetic Resonance Imaging
5%
Consensus
5%
Immunology and Microbiology
Immunoglobulin E
53%
Allergen
45%
Fish
38%
Allergy
32%
Extract
15%
Species
14%
Epitope
13%
ELISA
11%
Sensitization
10%
Neutrophil Granulocyte
9%
Basophil Granulocyte
9%
Cartilaginous Fish
8%
Programmed Death-Ligand 1
7%
Mastocytosis
7%
Lymphocyte
7%
Mast Cell
7%
Birch
7%
Salmonine
7%
Skin
6%
Allergenicity
6%
Shark
6%
Monospecific Antibody
6%
Pollen
5%
Pharmacology, Toxicology and Pharmaceutical Science
Drug
21%
Melanoma
17%
Allergen
15%
Biological Product
13%
Immunoglobulin E
13%
Survival
12%
Peanut
12%
Mycosis fungoides
12%
Neoplasm
11%
Etanercept
9%
Adalimumab
9%
Cutaneous T Cell Lymphoma
8%
Adverse Event
8%
Psoriasis
7%
Antibody
7%
Peptide
7%
Nitrogen Mustard
7%
Sorafenib
7%
Vicilin
7%
Monoclonal Antibody
7%
Liver Cell Carcinoma
7%
Fish
7%
Talimogene Laherparepvec
6%
Mitogen Activated Protein Kinase Kinase Inhibitor
6%
Metastatic Melanoma
6%
Infliximab
6%
Protein
6%
Survival Rate
5%
Juglans
5%
Fusion Protein
5%
Parvalbumin
5%